⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 1, 2024RMD OpenOpen Access

Urinary methotrexate dosage in rheumatoid arthritis, in patients treated for at least 6 months: a potential marker of adherence

N. Théate Marion Geoffroy Lukshe Kanagaratnam Claire Gozalo Isabelle Charlot L. Bolko Ambre Hittinger-Roux Zoubir Djerada Jean‐Hugues Salmon

View Full Paper

Ask AI

Bookmark

Share

Abstract

Non-adherence to rheumatoid arthritis (RA) treatments must be identified. A methotrexate (MTX) urinary dosage (METU) was recently developed. The aim of our study was to assess adherence to MTX in RA using METU in real-life conditions and to compare it with indirect adherence measurement technics.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Théate et al. (2024) studied this question.

synapsesocial.com/papers/68e6c339b6db6435876429bd https://doi.org/10.1136/rmdopen-2023-004024

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic ReviewSystematic Review · 2016 · 104 citations
2Predictors of methotrexate adherence and patient's awareness of it in rheumatoid arthritis and its effect on quality of life2024 · 2 citations
3Evaluation of Adherence to Methotrexate in a Sample of Iraqi Patients with Rheumatoid Arthritis Receiving Anti - TNF Medications2024
4#284 Risk of dose-dependent methotrexate therapy on renal functions in patients with rheumatoid arthritis2024
5Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled trialCross-Sectional Study · 2007 · 413 citations